Bioventus (BVS) Capital Expenditures (2020 - 2026)

Bioventus (BVS) has reported Capital Expenditures for 7 consecutive years, with $960000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 40.56% year-over-year to $960000.0; the trailing twelve-month figure through Jun 2026 stood at $2.6 million (up 20.49% YoY), and the FY2025 full-year result was $2.6 million, up 154.67% from the prior year.
• Capital Expenditures advanced to $960000.0 in Q2 2026 per BVS's latest filing, from $574000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.6 million in Q2 2023 and bottomed at -$5.2 million in Q4 2022.
• Historically, Capital Expenditures has averaged $774555.6 across 5 years, with a median of $631500.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures sank 157.65% in 2022, then soared 787.01% in 2025.
• Over 5 years, Capital Expenditures stood at -$5.2 million in 2022, then soared by 107.15% to $369000.0 in 2023, then jumped by 55.56% to $574000.0 in 2024, then gained by 1.05% to $580000.0 in 2025, then soared by 65.52% to $960000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $960000.0, $574000.0, and $580000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.